We are live on
!
Find out more
JC
JBF Capital Portfolio holdings
AUM
$764M
Turnover
38.35%
1-Year Est. Return
24.26%
This Fund
S&P 500
This Quarter
Est. Return
+3.71%
1 Year Est. Return
+24.26%
3 Year Est. Return
+93.63%
5 Year Est. Return
+127.41%
10 Year Est. Return
+469.69%
AUM
$664M
AUM Growth
+$30.9M
(+4.9%)
Cap. Flow
+$17.4M
Cap. Flow
% of AUM
2.62%
Top 10 Holdings %
Top 10 Hldgs %
86.89%
Holding
104
New
21
Increased
17
Reduced
11
Closed
16
Avg Time Held Equity + Options
0.8
years
Top 10 Avg Time Held Equity + Options
1.9
years
Top 20 Avg Time Held Equity + Options
1.3
years
Avg Time Held Equity only
0.8
years
Top 10 Avg Time Held Equity only
1.9
years
Top 20 Avg Time Held Equity only
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$11.7M |
| 2 |
Goldman Sachs
GS
|
+$9.54M |
| 3 |
Microsoft
MSFT
|
+$4.85M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$4.33M |
| 5 |
FCBP
First Choice Bancorp Common Stock
FCBP
|
+$2.55M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$12.1M |
| 2 |
Chord Energy
CHRD
|
+$5.69M |
| 3 |
GE Aerospace
GE
|
+$5.39M |
| 4 |
Mannatech
MTEX
|
+$1.28M |
| 5 |
Arcus Biosciences
RCUS
|
+$1.11M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 71.93% |
| 2 | Financials | 8.3% |
| 3 | Consumer Discretionary | 5.62% |
| 4 | Technology | 5.23% |
| 5 | Healthcare | 3.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
argenx
ARGX
$53.2B
| $1.74M | 0.26% |
20,990
-5,000
| -19% | -$447K |
2018 Q1
1 quarter
|
|
27
Cellectis
CLLS
$111M
| $1.7M | 0.26% |
+60,000
| New | +$1.79M |
2018 Q2
0 quarters
|
|
28
Princeton Bancorp
BPRN
$296M
| $1.66M | 0.25% |
50,000
| – | – |
2017 Q4
2 quarters
|
|
29
DELISTED
Catalyst Pharmaceutical
CPRX
| $1.59M | 0.24% |
508,600
+50,000
| +11% | +$152K |
2018 Q1
1 quarter
|
|
|
CCT
30
DELISTED
Corporate Capital Trust, Inc.
CCT
| $1.56M | 0.24% |
+100,000
| New | +$1.66M |
2018 Q2
0 quarters
|
|
31
CALL
Apple
AAPL
$4.99T
| $1.5M | 0.23% |
4,000
| – | – |
2018 Q1
1 quarter
|
|
32
DELISTED
Blueprint Medicines
BPMC
| $1.42M | 0.21% |
22,322
+11,500
| +106% | +$915K |
2018 Q1
1 quarter
|
|
|
GCAP
33
DELISTED
Gain Capital Holdings, Inc.
GCAP
| $1.33M | 0.2% |
176,800
| – | – |
2017 Q4
2 quarters
|
|
34
DELISTED
iPath S&P 500 VIX Short-Term Futures ETN due 1/30/2019
VXX
| $1.32M | 0.2% |
35,590
-14,410
| -29% | -$557K |
2018 Q1
1 quarter
|
|
|
35
Chord Energy
CHRD
$8.11B
| $1.3M | 0.2% |
100,000
-500,000
| -83% | -$5.69M |
2017 Q4
2 quarters
|
|
36
BlueLinx
BXC
$576M
| $1.2M | 0.18% |
31,900
+4,000
| +14% | +$156K |
2017 Q4
2 quarters
|
|
37
DELISTED
Audentes Therapeutics, Inc
BOLD
| $1.2M | 0.18% |
31,300
+10,000
| +47% | +$370K |
2018 Q1
1 quarter
|
|
38
Reading International Class A
RDI
$41M
| $1.19M | 0.18% |
74,325
| – | – |
2017 Q4
2 quarters
|
|
|
AMRWW
39
CALL
DELISTED
Alta Mesa Resources Inc Warrant
AMRWW
| $1.04M | 0.16% |
740,832
| – | – |
2018 Q1
1 quarter
|
|
|
FSACU
40
DELISTED
Federal Street Acquisition Corp. Unit
FSACU
| $1.01M | 0.15% |
100,000
| – | – |
2017 Q3
3 quarters
|
|
41
BioMarin Pharmaceuticals
BMRN
$10.8B
| $995K | 0.15% |
10,560
-2,000
| -16% | -$175K |
2018 Q1
1 quarter
|
|
|
MR
42
DELISTED
Montage Resources Corporation Common Stock
MR
| $980K | 0.15% |
40,825
| – | – |
2018 Q1
1 quarter
|
|
43
iShares MSCI Ireland ETF
EIRL
$76M
| $919K | 0.14% |
19,411
| – | – |
2016 Q1
9 quarters
|
|
44
Kyntra Bio
KYNB
$21.7M
| $883K | 0.13% |
564
+200
| +55% | +$261K |
2018 Q1
1 quarter
|
|
45
Bristol-Myers Squibb
BMY
$124B
| $863K | 0.13% |
15,600
+5,000
| +47% | +$270K |
2018 Q1
1 quarter
|
|
46
Walt Disney
DIS
$191B
| $744K | 0.11% |
7,100
| – | – |
2018 Q1
1 quarter
|
|
|
IRL
47
DELISTED
NEW IRELAND FUND INC
IRL
| $702K | 0.11% |
60,100
| – | – |
2016 Q1
9 quarters
|
|
48
Central Securities Corp
CET
$1.64B
| $697K | 0.11% |
25,000
| – | – |
2017 Q1
5 quarters
|
|
|
GBT
49
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $678K | 0.1% |
+15,000
| New | +$683K |
2018 Q2
0 quarters
|
|
50
Xencor
XNCR
$1.78B
| $625K | 0.09% |
16,900
| – | – |
2018 Q1
1 quarter
|
|
Similar funds
UCMOK
EIM
CAAM
KLI
CT
ANRF
NI
HI
JBF Capital's Q2 2018 Portfolio in Review
As of Q2 2018, JBF Capital held 104 positions worth $664M, up 4.9% from $633M the previous quarter. Its ten largest holdings account for 87% of the portfolio.
JBF Capital's Q2 2018 filing shows 21 new, 17 increased, 11 reduced and 16 closed positions. Its largest new stake was Tesla: 578,010 shares worth $13.2M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $12.1M.
By sector, the portfolio is most concentrated in Miscellaneous at 72% of assets, down from 76% a quarter earlier, followed by Financials and Consumer Discretionary.
- JBF Capital's largest Q2 2018 buy was Tesla: 578,010 shares worth $13.2M.
- JBF Capital added most to Microsoft in Q2 2018, an estimated $4.85M increase.
- JBF Capital's biggest Q2 2018 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $12.1M.
- JBF Capital fully exited GE Aerospace in Q2 2018, selling an estimated $5.39M.
- JBF Capital's ten largest holdings make up 87% of its $664M portfolio in Q2 2018.
- JBF Capital opened 21 new positions and closed 16 in Q2 2018.
- JBF Capital's portfolio value rose 4.9% quarter-over-quarter to $664M.
Based on JBF Capital's 13F filing for Q2 2018, filed 9 Aug 2018.